Bladder Cancer
Prostate Cancer
EAU Edu Platform on Kidney Cancer
Home
Articles
Article of the Month
Editorials
Videos
Webcasts
Education
E-courses
Webinars
Online curriculum
Guidelines
Events
Home
Articles
Terug
Article of the Month
Editorials
Videos
Webcasts
Education
Terug
E-courses
Webinars
Online curriculum
Guidelines
Events
Upcoming event
ASCO Annual Meeting 2023
Home
/
Articles
Back
EAU2023
ASCO GU2023
ESMO22
EAU2022
AUA2022
ASCO GU2022
ASCO21
Article of the Month
Filter
Tags
Article of the Month
,
ASCO GU22
,
ASCO21
,
AUA21
,
Cabozantinib
,
Carcinoma
,
Chronic kidney disease
,
Cryosurgery
,
EAU
,
EAU21
,
EAU22
,
EMUC21
,
EMUC22
,
ERUS22
,
ESMO21
,
Frail patient​
,
Glomerular filtration rate
,
Guidelines
,
IMDC risk model
,
Kidney cancer
,
Laparoscopy
,
Lymph node metastases
,
Lymph nodes
,
Metastasectomy
,
Mortality
,
Neoplasm metastasis
,
Neoplasm recurrence
,
Nephrectomy
,
Nephron-sparing surgery
,
Nivolumab
,
Overall survival
,
Partial nephrectomy
,
Prognostication
,
Radical nephrectomy
,
Radical surgery
,
RCC
,
Renal cancer
,
Renal cell
,
Renal cell carcinoma
,
Renal Cell Carcinoma guidelines
,
Renal cryoablation
,
Renal function
,
Renal Transplantation
,
Renorrhaphy
,
Robotic
,
Robotic prostatectomy
,
Robotic surgery
,
Survival outcome
,
Suture
,
Targeted therapies
,
Treatment response
,
Urological surgery
,
UROwebinar
,
Webinar
Show all
Patient-reported outcome measurement and reporting for patients with advanced renal cell carcinoma: A systematic literature review
European Urology, August 2023
View
Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study
The LANCET
View
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
View
Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time
BJU International, March 2023
View
Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma
European Urology Oncology, October 2023
View
Oncological and peri-operative outcomes of percutaneous cryoablation of renal cell carcinoma for patients with hereditary RCC diseases – An analysis of European multi-centre prospective EuRECA registry
View
Is adjuvant immunotherapy worth for all patients with clear-cell renal cell carcinoma at high risk of recurrence?
View
Deciphering the relationship between pathogenic variants and clinical phenotype in VHL patients: results from a prospective observational study
View
Development of an individual postoperative prediction model for kidney cancer recurrence using machine learning (UroCCR study 120)
View
Quality of life outcomes after robotic-assisted versus open partial nephrectomy: Results from the randomized ROBOCOP II trial
View
89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma – results from phase 3 ZIRCON study
View
Local treatment of recurrent renal cell carcinoma may have a significant survival effect across all risk-of-recurrence groups
European Urology Open Science, January 2023
View
Next